Akribion Therapeutics

Executive Summary

Akribion Therapeutics is a German biotechnology company pioneering a novel class of RNA-guided, nuclease-based therapeutics for programmable cell depletion. Founded in 2021 and headquartered in Munich, the company has developed a proprietary G-dase® E payload that enables precise targeting and elimination of diseased cells based on their intracellular RNA signatures. Akribion's initial focus is on precision oncology, starting with HPV-induced Oropharyngeal Squamous Cell Carcinoma (OPSCC), a cancer with high unmet need. The technology offers a differentiated approach to cell depletion, potentially providing a new therapeutic modality with improved specificity and reduced off-target effects compared to traditional therapies.

Upcoming Catalysts (preview)

• Q4 2025IND/CTA Filing for Lead Program in HPV+ OPSCC75% success
• Q2 2025Preclinical Proof-of-Concept Data Publication80% success
• Q3 2025Series A Financing Round70% success